 |
Find a Stock's Home Page |
|
| News |
San Diego, CA 7/01/2009
Medical research company Spherix Inc. (SPEX) watched its shares rally to a high of $2.67 after recently announcing encouraging news regarding its diabetes product Naturlose. Since then, however, investors have lost interest as shares have fallen back to the current price around $1.38. Is the company's diabetes treatment less than hoped despite the initial gains observed from the stock? A brief company and trading analysis has been posted at the Small Cap network website.
Investors and small cap enthusiasts who want to review the commentary as well as receive exclusive stocks picks and market analysis can subscribe to the site's newsletter by visiting: http://access.smallcapnetwork.com/t/
Spherix Inc. (SPEX) recently published positive results for a Phase II study of the diabetes drug Naturlose(r) (D-tagatose), which was largely the cause for the temporary surge in share price. The same drug is involved in a separate diabetes treatment study currently in Phase III. Naturlose is the registered brand name for tagatose, a natural sugar that's often used as a low-calorie and full-bulk sweetener. Spherix also offers consulting services to biotechnology and pharmaceutical companies to meet a variety of needs, including safety analysis of food ingredients, and safety analysis of pharmaceutical equipment. SPEX's market cap is just under $20 million.
About Us
The comments and outlooks offered by Small Cap Network's research staff combine technical and fundamental approaches that not only find the attractive stocks. but also determine the ideal times to buy or sell them. The organization's broad market-based calls draw on decades worth of investing experience, and an effective combination of breadth and depth tools.
The website, which emphasizes small cap stock trading, posts its individual stock picks and market calls daily on its website. Highlights of those commentaries are e-mailed to subscribers through a complimentary newsletter. To register for the newsletter or learn more about today's focus stocks, investors can go to: access.smallcapnetwork.com/t/.
The website and its interactive community pages are becoming one of the web's preferred destinations for active investors searching for unbiased small cap and micro cap commentary. The free newsletter provides the site's highlights for those who receive it, while the blog and community pages provide an enormous amount of exclusive commentary on the undercovered small cap segment of the equity market.
Forward-Looking Statement:
This press release may include or imply "forward-looking statements" within the meaning of the federal securities laws, commonly identified by such terms as "believes," "looking ahead," "anticipates," "estimates" and other terms with similar meaning. Although the Company believes that the assumptions upon which its forward-looking statements are based are reasonable, it can give no assurance that these assumptions will prove to be correct. Important factors that could cause actual results to differ materially from the Company's projections and expectations are disclosed in the Company's filings with the Securities and Exchange Commission. All forward-looking statements in this press release are expressly qualified by such cautionary statements and by reference to the underlying assumptions.
SmallCapNetwork.com is not a registered investment adviser or broker/dealer. SmallCapNetwork.com makes no recommendation that the purchase of securities of companies profiled in this website is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for many of their securities, investing in such securities is highly speculative and carries a high degree of risk.
Contact Information:
Small Cap Network
4653 Carmel Mtn. Rd
Suite 308 #402
San Diego, CA 92130
Email: editor@smallcapnetwork.com
Source: Small Cap Network
http://community.smallcapnetwork.com/Todays-Penny-Stock-Hot-Spots-VICL-TSTR-SPEX-IGNT/s/article/view/p/mid/2/id/40/
